<DOC>
	<DOCNO>NCT02314026</DOCNO>
	<brief_summary>This study 's aim develop algorithm ¹³C-Octanoate Breath Test without ¹³C-Methacetin Breath Test ( OBT MBT respectively ) correlation histological finding associate Non-Alcoholic Steatohepatitis ( NASH ) liver diseases use BreathID® System</brief_summary>
	<brief_title>BREATHID Octanoate Breath Test With Without Methacetin Breath Test Correlation With Biopsy NASH</brief_title>
	<detailed_description>Non-Alcoholic Steatohepatitis ( NASH ) grow epidemic western world due contemporary eating habit life styles.NASH lead cirrhosis , hepatic carcinoma liver complication . There currently treatment available . The definitive way detect NASH patient advance liver disease liver biopsy . However , liver biopsy disadvantage , sample error , chance complication lend follow treatment . A non-invasive test could potentially replace biopsy aid NASH detection treatment monitoring , would improve management suspected NASH patient without need biopsy . This protocol obtain result one two different breath test provide accurate evaluation liver status patient high risk NASH .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Adult men woman ( ≥18 year age ) 2 . Liver biopsy , indicate NAFLD/NASH , perform within 6 month prior breath test OR undergo liver biopsy ruleout confrim NAFLD/NASH . NOTE : The sample obtain meet defined quality criterion . ( In Appendix II protocol ) 3 . Any elevation liver enzymes upper limit normal ( follow : AST , ALT , GGT , Alkaline phosphatase ) least 3 month 4 . No known coexistent liver disease , exclude appropriate serologic / test 5 . Imaging US / CT / MRI ( available ) typical image Fatty Liver suggestive NASH . 6 . Patient ( legal guardian ) able willing sign Informed Consent Form 7 . Can tolerate overnight ( 8hour ) fast 1 . Positive study follow within three year prior biopsy : 1 . Anti HCV positive 2 . Anti HB core antibody positive 3 . Iron saturation &gt; 60 % + gene test hereditary hemochromatosis iron overload define presence 3+ 4+ stainable iron liver biopsy 4 . Antinuclear antibody titer &gt; 1 : 160 along hypergammaglobulinemia 5 time ALT normal level 5 . Alpha1antitrypsin level lower limit normal ( &lt; 150 mg/dl ) PAS diastase resistant globule biopsy . 6 . Primary biliary cirrhosis define elevation alkaline phosphatase great upper limit normal antimitochondrial antibody ( AMA ) great 1:80 consistent liver histology 7 . Low level ceruloplasmin 8 . Druginduced liver disease define basis typical exposure history 2 . Patients know chronic liver disease NAFLD routinely diagnose investigator 3 . Concurrent acute hepatic condition NAFLD 4 . Alcohol consumption &gt; 20 gm/day ( 0.71 oz/day ) woman &gt; 30 gm/day ( 1.06 oz/day ) men 5 . Drugs may interfere octanoate metabolism also cause NAFLD independent metabolic syndrome , include : corticosteroid , amiodarone , tetracycline , valproic acid , methotrexate , stavudine , zidovudine 6 . When MBT perform subject take follow least 48 hour prior breath test : Acyclovir , allopurinol , carbamazepine , cimetidine , ciprofloxacin , daidzein , ( herbal ) disulfiram , echinacea , enoxacin , famotidine , fluvoxamine , methoxsalen , mexiletine , montelukast , norfloxacin , phenylpropanolamine , phenytoin , propafenone , rifampin , terbinafine , ticlopidine , thiabendazole , verapamil , zileuton medication might interfere Methacetin metabolism might affect CYP 1A2 7 . Patients 10 % weight change biopsy enrollment . 8 . Hypersensitivity study substrate ; i.e . Octanoate Methacetin respectively 9 . Known extrahepatic disease include limited : severe congestive heart failure ( NIHA &gt; 2 ) , know severe pulmonary hypertension ( &gt; 35 mmHg ) , history chronic obstructive pulmonary disease uncontrolled symptomatic bronchial asthma uncontrolled diabetes mellitus ( HA1c &gt; 9.5 % ) 10 . Previous surgical GI bypass surgery 11 . Extensive small bowel resection ( &gt; 100 cm ) 12 . Known uncontrolled malabsorption diarrhea 13 . Concurrent total parenteral nutrition 14 . Any organ transplant 15 . Patients receive antiviral treatment liver direct therapy , procedure surgery time biopsy breath test 16 . Pregnant breast feed 17 . Patients and/or legal guardian unable refuse sign inform consent 18 . Patients , base opinion investigator , enrol study due safety / adherence reason . 19 . Patients participate clinical trial already receive experimental treatment procedures 20 . Patients suspect documented hepatocellular carcinoma ultrasound image modality 21 . Patients diagnose partial / complete portal venous occlusion , hepatic venous occlusion , previous PHT surgery , placement transjugular intrahepatic portosystemic shunt ( TIPS ) accord initial imaging study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>